Contact Us
Drug Search Results
More Filters [+]

AVE-1642

Alternative Names: ave-1642, ave1642, ave 1642
Latest Update: 2021-12-20
Latest Update Note: News Article

Product Description

a therapeutic antibody that binds to the Insulin-like Growth Factor 1 Receptor (IGF-1R)

Mechanisms of Action: IGF Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AVE-1642

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatocellular Carcinoma|Breast Cancer

Phase 1: Multiple Myeloma|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2008-000810-54

P2

Completed

Breast Cancer

2010-11-10

TCD10631

P2

Terminated

Breast Cancer

2010-11-01

2006-005978-51

P1

Completed

Oncology Solid Tumor Unspecified

2009-12-21

TED10630

P2

Terminated

Hepatocellular Carcinoma

2009-11-01

Recent News Events

Date

Type

Title

12/20/2021

News Article

 Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

10/14/2021

News Article

 Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration

03/23/2021

News Article

 Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies

10/28/2020

News Article

 miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions